19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
For international investors looking at opportunities in China, this summer has been largely a waitin...
Read More >
The Ninth Circuit ruled that a California Matco Tool franchisee, John Fleming, could bring a class a...
Read More >
Changes on the horizon will require employers throughout New York State to make significant changes ...
Read More >
Report on Supply Chain Compliance 3, no. 1 (January 9, 2020) - A young girl in the United Kingdom f...
Read More >
The United States Army Corps of Engineers (Little Rock District) (“Corps”) issued a November 6th P...
Read More >
New Act 250 board proposal is gutted - The House Committee on Ways and Means voted 9-1 this week in...
Read More >